Abstracts tagged "Outcome measures"

Abstract Number: 0866 • ACR Convergence 2021
Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Cristina Reategui-Sokolova⁵, Ann Clarke⁶, Leanna Wise⁷, Guillermo Pons-Estel⁸, Maria José Santos⁹, Sasha Bernatsky¹⁰, Sandra Lúcia Ribeiro¹¹, Samar Al Emadi¹², Jeffrey Sparks¹³, Tiffany Hsu¹⁴, Kristin D'Silva¹⁵, Naomi Patel¹⁵, Emily Gilbert¹⁶, Maria Valenzuela-Almada¹⁷, Andreas Jnsen¹⁸, Gianpiero Landolfi¹⁹, Micaela Fredi²⁰, Tiphaine Goulenok²¹, Mathilde Devaux²², Xavier Mariette²³, Viviane Queyrel²⁴, Vasco C Romão²⁵, Graça Sequeira²⁶, Rebecca Hasseli²⁷, Bimba Franziska Hoyer²⁸, Reinhard Voll²⁹, Christof Specker³⁰, Roberto Baez³¹, Vanessa Castro Coello³², Edgard Neto³³, Gilda Ferreira³⁴, Odirlei Andre Monticielo³⁵, Emily Sirotich³⁶, Jean Liew³⁷, Jonathan Hausmann³⁸, Paul Sufka³⁹, Rebecca Grainger⁴⁰, Suleman Bhana⁴¹, Wendy Costello⁴², Zachary Wallace⁴³, Lindsay Jacobsohn⁴⁴, Anja Strangfeld⁴⁵, Elsa Frazão Mateus⁴⁶, Kimme Hyrich⁴⁷, Laure Gossec⁴⁸, Loreto Carmona¹, Saskia Lawson-Tovey⁴⁷, Lianne Kearsley-Fleet⁴⁹, Martin Schaefer⁵⁰, Pedro Machado⁵¹, Philip Robinson⁵², Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶University of Calgary, Calgary, AB, Canada, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR), Rosario, Argentina, ⁹Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰McGill University, Montréal, QC, Canada, ¹¹Universidade Federal do Amazonas, Amazonas, Brazil, ¹²Hamad medical corporation, Doha, Qatar, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁵Massachusetts General Hospital, Boston, MA, ¹⁶Mayo Clinic, Jacksonville, FL, ¹⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Lund University, Lund, Sweden, ¹⁹Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Internal Medicine Department, Bichat Claude Bernard Hospital, Paris, France, ²²Service de Médecine Interne, CHI Poissy Saint Germain, Poissy, France, ²³Université Paris- Saclay, Rheumatology, Paris, France, ²⁴University Hospital of Nice, Nice, France, ²⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²⁶Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal, ²⁷Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁸Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ³⁰Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ³¹Hospital Francisco Lopez Lima, General Roca, Rio Negro, Argentina, ³²Sanatorio Güemes, Buenos Aires, Argentina, ³³UNIFESP, São Paulo, Brazil, ³⁴Federal University of Minas Gerais, Belo Horizonte, Brazil, ³⁵Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³⁶McMaster University, Hamilton, ON, Canada, ³⁷Boston University, Boston, MA, ³⁸Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ³⁹HealthPartners, Eagan, MN, ⁴⁰University of Otago, Wellington, New Zealand, ⁴¹Crystal Run Health, Montvale, NJ, ⁴²Irish Children's Arthritis Network, Bansha, Ireland, ⁴³Massachusetts General Hospital, Newton, MA, ⁴⁴University of California San Francisco, Antioch, CA, ⁴⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁶Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁴⁷University of Manchester, Manchester, United Kingdom, ⁴⁸Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁴⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁰German Rheumatism Research Center, Berlin, Germany, ⁵¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵²Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Preliminary data in people with SLE suggested that disease activity as well as SLE treatment at time of COVID-19 acquisition impact COVID-19 outcomes over…
Abstract Number: 1290 • ACR Convergence 2021
Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials
Michal Abrahamowicz¹ and Peter Lipsky², ¹McGill University, Montréal, QC, Canada, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of effective new Systemic Lupus Erythematosus (SLE) treatments requires a validated responder index responsive to clinically meaningful change and relevant to clinical practice.…
Abstract Number: 1931 • ACR Convergence 2021
The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis
Ashu Acharya¹, Saffa Iftikhar¹, Yasmin Khader¹, Sachit Sharma¹, Joan N Gekonde¹, Rawish Fatima¹, Cameron J Burmeister¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic immune-mediated disease with 20-25% patients needing hospital admission annually. Early readmissions add to the clinical and economic…
Abstract Number: 0400 • ACR Convergence 2021
Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
John Pauling¹, Lesley Ann Saketkoo², Dinesh Khanna³, Christopher Denton⁴, Tracy Frech⁵, Ariane Herrick⁶, Laura Hummers⁷, Ami Shah⁸ and Robyn Domsic⁹, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ³University of Michigan, Ann Arbor, MI, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁵University of Utah, Salt Lake City, UT, ⁶University of Manchester, Salford, United Kingdom, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The episodic and uniquely personalised nature of Raynaud’s phenomenon (RP) has led to reliance upon self-report to capture how patients ‘feel’ and ‘function’. Existing…
Abstract Number: 0737 • ACR Convergence 2021
Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
Sumir Brahmbhatt¹, Ahsan Iqbal¹, Fatemeh Farshami², Maheswari Muruganandam³, Jaren Trost⁴, David Cisneros⁵, Adnan Kiani³, N. Suzanne Emil³, Sharon Nunez¹, William Hayward⁶, Philip Band⁷ and Wilmer Sibbitt³, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, MD, ³University of New Mexico, Albuquerque, NM, ⁴Optum, Albuquerque, NM, ⁵University of New Mexico School of Medicine, Albuquerque, NM, ⁶New Mexico Highlands University, Las Vegas, NM, ⁷NYU SOM, New York, NY
Background/Purpose: To explore an alternative to standard extended knee arthrocentesis using pneumatic compression of the flexed knee.Methods: Using a paired sample design, 41 consecutive effusive…
Abstract Number: 0877 • ACR Convergence 2021
Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
Kai Sun¹, Amanda Eudy², Jennifer Rogers¹, Lisa Criscione-Schreiber¹, Rebecca Sadun², Jayanth Doss², Kelley Brady³, Roberta Alexander³, John Conklin³, Rory Bloch³ and Megan Clowse⁴, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Exagen Inc., Vista, CA, ⁴Duke University, Chapel Hill, NC
Background/Purpose: HCQ levels reflect adherence and have been shown to correlate with SLE outcomes. However, HCQ levels have not been studied in the context of…
Abstract Number: 1299 • ACR Convergence 2021
Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network
Peter Izmirly¹, Maria Dall'Era², Kenneth Kalunian³, Kristina Deonaraine¹, Mimi Kim⁴, Philip Carlucci¹, Jessica Li⁵, Andrea Fava⁵, H. Michael Belmont⁶, Chaim Putterman⁷, Jennifer Anolik⁸, Betty Diamond⁹, David Wofsy¹⁰, Diane Kamen¹¹, Judith James¹², Accelerating Medicines Partership (AMP) RA/SLE Network¹³, Deepak Rao¹⁴, The Accelerating Medicines Partnership in SLE Network¹⁵, Michelle Petri¹⁶, Jill Buyon⁶ and Richard Furie¹⁷, ¹New York University School of Medicine, New York, NY, ²University of California San Francisco, Corte Madera, CA, ³UC San Diego, La Jolla, CA, ⁴Albert Einstein College of Medicine, Larchmont, NY, ⁵Johns Hopkins University, Baltimore, MD, ⁶NYU School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Bronx, NY, ⁸University of Rochester Medical Center, Rochester, NY, ⁹Northwell Health, Manhasset, NY, ¹⁰University of California San Francisco, San Francisco, CA, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Brigham and Women's Hospital, Everett, MA, ¹⁴Brigham and Women's Hospital, Boston, MA, ¹⁵Multiple Institutions, Multiple Cities, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…
Abstract Number: 1933 • ACR Convergence 2021
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Emily Gilbert⁵, Maria Valenzuela-Almada⁶, Leanna Wise⁷, Jeffrey Sparks⁸, Tiffany Hsu⁹, Kristin D'Silva¹⁰, Naomi Patel¹⁰, Emily Sirotich¹¹, Jean Liew¹², Jonathan Hausmann¹³, Paul Sufka¹⁴, Rebecca Grainger¹⁵, Suleman Bhana¹⁶, Wendy Costello¹⁷, Zachary Wallace¹⁸, Lindsay Jacobsohn¹⁹, Anja Strangfeld²⁰, Elsa Frazão Mateus²¹, Kimme Hyrich²², Laure Gossec²³, Loreto Carmona²⁴, Saskia Lawson-Tovey²², Lianne Kearsley-Fleet²⁵, Martin Schaefer²⁶, Pedro Machado²⁷, Philip Robinson²⁸, Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Jacksonville, FL, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Boston University, Boston, MA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁴HealthPartners, Eagan, MN, ¹⁵University of Otago, Wellington, New Zealand, ¹⁶Crystal Run Health, Montvale, NJ, ¹⁷Irish Children's Arthritis Network, Bansha, Ireland, ¹⁸Massachusetts General Hospital, Newton, MA, ¹⁹University of California San Francisco, Antioch, CA, ²⁰Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ²¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ²²University of Manchester, Manchester, United Kingdom, ²³Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²⁴Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ²⁵Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²⁶German Rheumatism Research Center, Berlin, Germany, ²⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²⁸Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…
Abstract Number: 0401 • ACR Convergence 2021
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…
Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0925 • ACR Convergence 2021
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
Philip Mease¹, Robert McLean², Taylor Blachley², Maya Marchese², Laura Anatale-Tardiff³, Christopher Saffore⁴, Danny Quach⁵, Ana Biljan⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie Inc., Chicago, IL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…
Abstract Number: 1344 • ACR Convergence 2021
Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs
Alexis Ogdie¹, Robert McLean², Maya Marchese², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Kevin Douglas⁵, Danny Quach⁵ and Philip Mease⁶, ¹University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is a common goal for disease control when managing PsA. The aim of this study was to assess the association…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0751 • ACR Convergence 2021
Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?
Philip Mease¹, Vibeke Strand², Dan Furst³, Evan Siegel⁴, Melissa Mcilraith⁵, Elaine Husni⁶ and M. Cameron Hay⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford University School of Medicine, Portola Valley, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴Arthritis and Rheumatism Associates, Potomac, MD, ⁵M.Mc. Consulting, Dallas, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷Miami University (Ohio), Oxford, OH
Background/Purpose: Psoriatic Arthritis (PsA) affects multiple attributes of patient health; to assess treatment effectiveness a compilation of Patient Reported Outcomes (PRO) have been utilized. While…
Abstract Number: 1026 • ACR Convergence 2021
Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
Sung Kyung Cho¹, Lorinda Chung² and David Fiorentino³, ¹University of Texas Southwestern, Dallas, TX, ²Stanford University, Palo Alto, CA, ³Stanford University, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.